Kevin Meng

Kevin Meng is a Senior Research Scientist II at BioNTech SE since January 2022, with prior experience as a Senior Research Scientist at Fate Therapeutics Inc and Kite Pharma. At Fate Therapeutics Inc, Kevin focused on augmenting trafficking and persistence in iPSC-derived CAR/TCR T cells for solid tumor indications. At Kite Pharma, responsibilities included developing strategies to enhance TCR-T cell immunotherapy and discovering novel TCRs for preclinical pipelines. Kevin's research experience also encompasses a role as a Graduate Research Assistant at Stanford University School of Medicine, where work involved investigating the regulation of T cell activation and function through mechanical properties. Educational credentials include a Ph.D. in Microbiology and Immunology from Stanford University School of Medicine and a B.S. in Microbiology from the University of Maryland.